Equity Overview
Price & Market Data
Price: $6.49
Daily Change: +$0.06 / 0.92%
Daily Range: $6.34 - $6.68
Market Cap: $61,824,000
Daily Volume: 25,571
Performance Metrics
1 Week: -4.46%
1 Month: -14.50%
3 Months: -19.18%
6 Months: -59.34%
1 Year: -32.23%
YTD: -22.73%
Company Details
Employees: 102
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.